AMENDED AND RESTATED EXCLUSIVE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTExclusive License, Development and Commercialization Agreement • August 3rd, 2018 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
This Amended and Restated Exclusive License, Development and Commercialization Agreement (this “Agreement”) is made effective as of July 5, 2018 (the “Effective Date”) by and between Pacira Pharmaceuticals, Inc., a California corporation with a principal place of business at 5 Sylvan Way, Parsippany, New Jersey U.S. 07054 (“Pacira”) and Aratana Therapeutics, Inc., a Delaware corporation with a place of business at 11400 Tomahawk Creek Parkway Suite 340 Leawood, KS 66211 (“Aratana”). Pacira and Aratana are each hereafter referred to individually as a “Party” and together as the “Parties.”
PACIRA PHARMACEUTICALS, INC. and ARATANA THERAPEUTICS, INC. AMENDED AND RESTATED SUPPLY AGREEMENT DATED AS OF JULY 5, 2018Supply Agreement • August 3rd, 2018 • Aratana Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
THIS AMENDED AND RESTATED SUPPLY AGREEMENT (this “Agreement”) is made effective as of July 5, 2018 (the “Effective Date”) by and between Pacira Pharmaceuticals, Inc., a California corporation with a principal place of business at 5 Sylvan Way, Parsippany, New Jersey 07054 (“Pacira”) and Aratana Therapeutics, Inc., a Delaware corporation with a place of business at 11400 Tomahawk Creek Parkway Suite 340 Leawood, KS 66211 (“Aratana”). Pacira and Aratana are each hereafter referred to individually as a “Party” and together as the “Parties.” Capitalized terms used herein and not otherwise defined herein shall have the meanings set forth in Section 1.
